Trial Profile
BCT 1702 (CHARIOT): A phase II study evaluating efficacy and safety of Ipilimumab and Nivolumab with neoadjuvant weekly paclitaxel after anthracycline based chemotherapy in high-risk primary triple negative breast cancer, followed by definitive surgery and one year total duration of Nivolumab.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 10 Jul 2022
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Paclitaxel
- Indications Early breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms CHARIOT
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 22 Apr 2020 Status changed from recruiting to active, no longer recruiting.
- 12 Oct 2018 Status changed from not yet recruiting to recruiting.